Clinical Trial Update: A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing PROCRIT (epoetin alfa) dosing every two weeks versus once weekly in anemic HIV-infected patients; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• HIV Infection

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia, HIV | Phase 2 | Status: TERMINATED